Presentations

Presentations

RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)

Event: American Academy of Neurology (AAN) 2025 Annual Meeting (San Diego) View Abstract View News:…

徐春杰April 9, 2025

Presentations RAG-01 Presentation

First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(Abstract)

Event：40th Annual Congress of the European Association of Urology (EAU 2025) (Spain) View Abstract View…

徐春杰March 24, 2025

Presentations RAG-01 Presentation

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Event: 2024 Oligonucleotide Therapeutics Society Meeting (Montreal) View Abstract

ractigenOctober 11, 2024

Presentations

RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (Abstract)

Event: Society for Neuroscience Annual Meeting 2024 (Neuroscience 2024) (San Diego) View Abstract

徐春杰October 7, 2024

Presentations

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2024 TIDES Asia Conference (Tokyo Japan) View Poster

ractigenMarch 21, 2024

Presentations

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

EnvisionNovember 2, 2023

Presentations

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

EnvisionNovember 2, 2023

Presentations RAG-01 Presentation

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

Event: 2023 American Society of Clinical Oncology Meeting (Chicago) View Abstract

EnvisionJune 7, 2023

Presentations RAG-17 Presentation

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Event: 2023 TIDES USA (San Diego) View Poster

EnvisionMay 12, 2023

Presentations RAG-17 Presentation

Local administration of a novel siRNA conjugate (siRNA-ACO) into the CNS extends survival and improves motor function in the SOD1G93A mouse model for ALS (Poster)

Event: 2023 TIDES ASIA (Kyoto, Japan) View Poster

EnvisionMarch 10, 2023

RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)

First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(Abstract)

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (Abstract)

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Local administration of a novel siRNA conjugate (siRNA-ACO) into the CNS extends survival and improves motor function in the SOD1G93A mouse model for ALS (Poster)

Join Us

CONTACT US

Follow Us